TetraLogic Pharmaceuticals Return on Equity

TetraLogic Pharmaceuticals (TLOG) currently reports a ROE of 147.9%. That is above the Healthcare sector average of 20.86%. Use the charts on this page to explore TetraLogic Pharmaceuticals's ROE history and peer comparisons.

TetraLogic Pharmaceuticals's ROE of 147.9% is higher than the Healthcare sector average of 20.86%. That is roughly 609.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but TetraLogic Pharmaceuticals's current 147.9% should be judged against Healthcare norms (sector average: 20.86%) and against TLOG's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 147.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for TetraLogic Pharmaceuticals, and consider following TLOG for alerts when major investors trade the stock.

TetraLogic Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 147.9% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TLOG with unrelated industries.